STOCK TITAN

Compass Therapeutics Inc - CMPX STOCK NEWS

Welcome to our dedicated news page for Compass Therapeutics (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Compass Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Compass Therapeutics's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.92%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.1%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.53%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.8%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
conferences
Compass Therapeutics Inc

Nasdaq:CMPX

CMPX Rankings

CMPX Stock Data

222.89M
102.85M
13.44%
62.82%
1.18%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Boston

About CMPX

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond